{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T06:20:42Z","timestamp":1790144442625,"version":"4.0.1"},"reference-count":78,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,7,13]],"date-time":"2024-07-13T00:00:00Z","timestamp":1720828800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","cghjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Gastroenterology and Hepatology"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1016\/j.cgh.2024.06.036","type":"journal-article","created":{"date-parts":[[2024,7,16]],"date-time":"2024-07-16T20:10:58Z","timestamp":1721160658000},"page":"480-489","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":29,"title":["The Future of Clinical Trials in Inflammatory Bowel Disease"],"prefix":"10.1016","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4698-9948","authenticated-orcid":false,"given":"Christopher","family":"Ma","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Virginia","family":"Solitano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvio","family":"Danese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vipul","family":"Jairath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cgh.2024.06.036_bib1","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.2174\/1389450115666140908125738","article-title":"Catching the therapeutic window of opportunity in early Crohn's disease","volume":"15","author":"Danese","year":"2014","journal-title":"Curr Drug Targets"},{"key":"10.1016\/j.cgh.2024.06.036_bib2","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1053\/j.gastro.2022.01.024","article-title":"Disease monitoring in inflammatory bowel disease: evolving principles and possibilities","volume":"162","author":"Plevris","year":"2022","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2024.06.036_bib3","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1053\/j.gastro.2020.12.031","article-title":"STRIDE-II: an update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) initiative of the International Organization for the Study of IBD (IOIBD): determining therapeutic goals for treat-to-target strategies in IBD","volume":"160","author":"Turner","year":"2021","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2024.06.036_bib4","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1053\/j.gastro.2020.10.065","article-title":"Selecting end points for disease-modification trials in inflammatory bowel disease: the SPIRIT consensus from the IOIBD","volume":"160","author":"Le Berre","year":"2021","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2024.06.036_bib5","doi-asserted-by":"crossref","first-page":"2711","DOI":"10.1097\/MIB.0000000000000909","article-title":"Interpreting registrational clinical trials of biological therapies in adults with inflammatory bowel diseases","volume":"22","author":"Ghosh","year":"2016","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.cgh.2024.06.036_bib6","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1093\/ecco-jcc\/jjad020","article-title":"Declining enrolment and other challenges in IBD clinical trials: causes and potential solutions","volume":"17","author":"Uzzan","year":"2023","journal-title":"J\u00a0Crohns Colitis"},{"key":"10.1016\/j.cgh.2024.06.036_bib7","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1053\/j.gastro.2019.08.020","article-title":"Competition for clinical trials in inflammatory bowel diseases","volume":"157","author":"Harris","year":"2019","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2024.06.036_bib8","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1053\/j.gastro.2021.09.078","article-title":"Breaking through the therapeutic ceiling: what will it take?","volume":"162","author":"Raine","year":"2022","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2024.06.036_bib9","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1053\/j.gastro.2023.10.033","article-title":"Integrating evidence to guide use of biologics and small molecules for inflammatory bowel diseases","volume":"166","author":"Dulai","year":"2024","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2024.06.036_bib10","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/S0016-5085(76)80163-1","article-title":"Development of a Crohn's disease activity index. National Cooperative Crohn's Disease Study","volume":"70","author":"Best","year":"1976","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2024.06.036_bib11","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1056\/NEJM198712243172603","article-title":"Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study","volume":"317","author":"Schroeder","year":"1987","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cgh.2024.06.036_bib12","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1053\/j.gastro.2019.02.050","article-title":"Improving clinical trial efficiency in gastroenterology","volume":"157","author":"Ma","year":"2019","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2024.06.036_bib13","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1111\/apt.13243","article-title":"Population pharmacokinetics-pharmacodynamics of vedolizumab in patients with ulcerative colitis and Crohn's disease","volume":"42","author":"Rosario","year":"2015","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.cgh.2024.06.036_bib14","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1016\/j.clinthera.2022.08.010","article-title":"Population pharmacokinetics and exposure-response analyses of ustekinumab in patients with moderately to severely active Crohn's disease","volume":"44","author":"Adedokun","year":"2022","journal-title":"Clin Ther"},{"key":"10.1016\/j.cgh.2024.06.036_bib15","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1016\/j.clinthera.2011.06.002","article-title":"Pharmacokinetic properties of infliximab in children and adults with Crohn's disease: a retrospective analysis of data from 2 phase III clinical trials","volume":"33","author":"Fasanmade","year":"2011","journal-title":"Clin Ther"},{"key":"10.1016\/j.cgh.2024.06.036_bib16","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1053\/j.gastro.2019.08.043","article-title":"Efficacy and safety of mirikizumab in a randomized phase 2 study of patients with ulcerative colitis","volume":"158","author":"Sandborn","year":"2020","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2024.06.036_bib17","doi-asserted-by":"crossref","first-page":"2444","DOI":"10.1056\/NEJMoa2207940","article-title":"Mirikizumab as induction and maintenance therapy for ulcerative colitis","volume":"388","author":"D'Haens","year":"2023","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cgh.2024.06.036_bib18","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1093\/ecco-jcc\/jjac150","article-title":"Most placebo-controlled trials in inflammatory bowel disease were underpowered because of overestimated drug efficacy rates: results from a systematic review of induction studies","volume":"17","author":"Bahnam","year":"2023","journal-title":"J\u00a0Crohns Colitis"},{"key":"10.1016\/j.cgh.2024.06.036_bib19","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1038\/s41575-023-00805-z","article-title":"Innovations to improve the efficiency of phase II IBD clinical trials","volume":"20","author":"Noor","year":"2023","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2024.06.036_bib20","doi-asserted-by":"crossref","first-page":"2354","DOI":"10.1053\/j.gastro.2021.02.062","article-title":"Therapeutic interleukin-6 Trans-signaling inhibition by olamkicept (sgp130Fc) in patients with active inflammatory bowel disease","volume":"160","author":"Schreiber","year":"2021","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2024.06.036_bib21","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/S2468-1253(18)30306-6","article-title":"A\u00a0composite disease activity index for early drug development in ulcerative colitis: development and validation of the UC-100 score","volume":"4","author":"Jairath","year":"2019","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2024.06.036_bib22","doi-asserted-by":"crossref","first-page":"i647","DOI":"10.1093\/ecco-jcc\/jjad212.0410","article-title":"P280 Comparative responsiveness of disease activity indices in moderately-to-severely active ulcerative colitis: a post-hoc analysis of the UNIFI trial","volume":"18","author":"Solitano","year":"2024","journal-title":"J\u00a0Crohns Colitis"},{"key":"10.1016\/j.cgh.2024.06.036_bib23","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1590\/s0004-2803.202000000-15","article-title":"Placebo use in the context of inflammatory bowel disease clinical trials","volume":"57","author":"Lasa","year":"2020","journal-title":"Arq Gastroenterol"},{"key":"10.1016\/j.cgh.2024.06.036_bib24","doi-asserted-by":"crossref","first-page":"2324","DOI":"10.1016\/j.cgh.2021.06.011","article-title":"Anti-TL1A antibody PF-06480605 safety and efficacy for ulcerative colitis: a phase 2a single-arm study","volume":"19","author":"Danese","year":"2021","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2024.06.036_bib25","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1038\/s41573-023-00638-0","article-title":"Application of Bayesian approaches in drug development: starting a virtuous cycle","volume":"22","author":"Ruberg","year":"2023","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.cgh.2024.06.036_bib26","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1093\/ecco-jcc\/jjab194","article-title":"Clinical, endoscopic, and safety placebo rates in induction and maintenance trials of Crohn's disease: meta-analysis of randomised controlled trials","volume":"16","author":"Almradi","year":"2022","journal-title":"J\u00a0Crohns Colitis"},{"key":"10.1016\/j.cgh.2024.06.036_bib27","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1016\/j.cgh.2019.08.025","article-title":"Response to placebo, measured by endoscopic evaluation of Crohn's Disease Activity, in a pooled analysis of data from 5 randomized controlled induction trials","volume":"18","author":"Duijvestein","year":"2020","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2024.06.036_bib28","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1111\/apt.14672","article-title":"Systematic review with meta-analysis: endoscopic and histologic placebo rates in induction and maintenance trials of ulcerative colitis","volume":"47","author":"Ma","year":"2018","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.cgh.2024.06.036_bib29","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1093\/ecco-jcc\/jjab135","article-title":"Systematic review and meta-analysis: clinical, endoscopic, histological and safety placebo rates in induction and maintenance trials of ulcerative colitis","volume":"16","author":"Sedano","year":"2022","journal-title":"J\u00a0Crohns Colitis"},{"key":"10.1016\/j.cgh.2024.06.036_bib30","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1093\/ibd\/izac231","article-title":"Predictors of clinical remission to placebo in clinical trials of Crohn's disease","volume":"29","author":"Wong","year":"2023","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.cgh.2024.06.036_bib31","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1016\/j.cgh.2022.08.015","article-title":"Predictors of placebo induction response and remission in ulcerative colitis","volume":"21","author":"Wong","year":"2023","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2024.06.036_bib32","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1136\/gutjnl-2011-301668","article-title":"Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebo-controlled trial","volume":"61","author":"Hueber","year":"2012","journal-title":"Gut"},{"key":"10.1016\/j.cgh.2024.06.036_bib33","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1016\/j.cgh.2023.09.010","article-title":"Vedolizumab, adalimumab, and methotrexate combination therapy in Crohn's disease (EXPLORER)","volume":"22","author":"Colombel","year":"2024","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2024.06.036_bib34","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/s12916-018-1017-7","article-title":"Adaptive designs in clinical trials: why use them, and how to run and report them","volume":"16","author":"Pallmann","year":"2018","journal-title":"BMC Med"},{"key":"10.1016\/j.cgh.2024.06.036_bib35","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1007\/s43441-021-00302-y","article-title":"The use of external controls in FDA regulatory decision making","volume":"55","author":"Jahanshahi","year":"2021","journal-title":"Ther Innov Regul Sci"},{"key":"10.1016\/j.cgh.2024.06.036_bib36","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1056\/NEJMra1510062","article-title":"Master protocols to study multiple therapies, multiple diseases, or both","volume":"377","author":"Woodcock","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cgh.2024.06.036_bib37","doi-asserted-by":"crossref","first-page":"i1811","DOI":"10.1093\/ecco-jcc\/jjad212.1128","article-title":"P998 Phase 2 basket design study evaluating the efficacy and safety of an anti-TL1A antibody (TEV-48574) in moderate to severe ulcerative colitis or Crohn's Disease (RELIEVE UCCD)","volume":"18","author":"Reinisch","year":"2024","journal-title":"J\u00a0Crohns Colitis"},{"key":"10.1016\/j.cgh.2024.06.036_bib38","doi-asserted-by":"crossref","DOI":"10.1053\/j.gastro.2024.04.020","article-title":"Basket, umbrella, and platform trials: the potential for master protocol-based trials in inflammatory bowel disease","author":"Honap","year":"2024","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2024.06.036_bib39","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.1016\/S0140-6736(22)00467-6","article-title":"Risankizumab as induction therapy for Crohn's disease: results from the phase 3 ADVANCE and MOTIVATE induction trials","volume":"399","author":"D'Haens","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.cgh.2024.06.036_bib40","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1016\/S0140-6736(22)00466-4","article-title":"Risankizumab as maintenance therapy for moderately to severely active Crohn's disease: results from the multicentre, randomised, double-blind, placebo-controlled, withdrawal phase 3 FORTIFY maintenance trial","volume":"399","author":"Ferrante","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.cgh.2024.06.036_bib41","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1016\/S0140-6736(23)00061-2","article-title":"Etrasimod as induction and maintenance therapy for ulcerative colitis (ELEVATE): two randomised, double-blind, placebo-controlled, phase 3 studies","volume":"401","author":"Sandborn","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.cgh.2024.06.036_bib42","doi-asserted-by":"crossref","first-page":"i709","DOI":"10.1093\/ecco-jcc\/jjac190.0712","article-title":"P582 Efficacy of etrasimod at week 52 among subjects who reached clinical response at week 12: post hoc analysis of the phase 3 ELEVATE UC 52 trial","volume":"17","author":"Vermeire","year":"2023","journal-title":"J\u00a0Crohns Colitis"},{"key":"10.1016\/j.cgh.2024.06.036_bib43","doi-asserted-by":"crossref","first-page":"i619","DOI":"10.1093\/ecco-jcc\/jjac190.0620","article-title":"P490 Etrasimod for the treatment of ulcerative colitis: up to 2.5 years of pooled safety data from global clinical trials","volume":"17","author":"Vermeire","year":"2023","journal-title":"J\u00a0Crohns Colitis"},{"key":"10.1016\/j.cgh.2024.06.036_bib44","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1053\/j.gastro.2023.08.038","article-title":"Guselkumab in patients with moderately to severely active ulcerative colitis: QUASAR phase 2b induction study","volume":"165","author":"Peyrin-Biroulet","year":"2023","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2024.06.036_bib45","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1111\/apt.13291","article-title":"Randomised clinical trial: a placebo-controlled study of intravenous golimumab induction therapy for ulcerative colitis","volume":"42","author":"Rutgeerts","year":"2015","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.cgh.2024.06.036_bib46","article-title":"Demonstrating Substantial Evidence of Effectiveness With One Adequate and Well-Controlled Clinical Investigation and Confirmatory Evidence","year":"2023","journal-title":"Guidance for Industry"},{"key":"10.1016\/j.cgh.2024.06.036_bib47","doi-asserted-by":"crossref","first-page":"1966","DOI":"10.1056\/NEJMoa2212728","article-title":"Upadacitinib induction and maintenance therapy for Crohn's disease","volume":"388","author":"Loftus","year":"2023","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cgh.2024.06.036_bib48","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1016\/j.cgh.2020.12.017","article-title":"Endoscopic assessment of inflammatory bowel disease activity in clinical trials","volume":"20","author":"Khanna","year":"2022","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2024.06.036_bib49","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.cgh.2006.11.001","article-title":"A\u00a0randomized, double-masked, placebo-controlled study of alicaforsen, an antisense inhibitor of intercellular adhesion molecule 1, for the treatment of subjects with active Crohn's disease","volume":"5","author":"Yacyshyn","year":"2007","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2024.06.036_bib50","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1136\/gutjnl-2016-312735","article-title":"Tofacitinib for induction and maintenance therapy of Crohn's disease: results of two phase IIb randomised placebo-controlled trials","volume":"66","author":"Panes","year":"2017","journal-title":"Gut"},{"key":"10.1016\/j.cgh.2024.06.036_bib51","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1053\/j.gastro.2021.09.035","article-title":"Inclusion of under-represented racial and ethnic minorities in randomized clinical trials for inflammatory bowel disease","volume":"162","author":"Cohen","year":"2022","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2024.06.036_bib52","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/S2468-1253(19)30333-4","article-title":"The global, regional, and national burden of inflammatory bowel disease in 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017","volume":"5","year":"2020","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2024.06.036_bib53","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1038\/ajg.2011.103","article-title":"Assessing response and loss of response to biological therapies in IBD","volume":"106","author":"Yanai","year":"2011","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.cgh.2024.06.036_bib54","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1056\/NEJMoa2208450","article-title":"Vedolizumab for the treatment of chronic pouchitis","volume":"388","author":"Travis","year":"2023","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cgh.2024.06.036_bib55","doi-asserted-by":"crossref","first-page":"i536","DOI":"10.1093\/ecco-jcc\/jjac190.0537","article-title":"P407 Efficacy and safety of etrasimod in subjects with moderately to severely active isolated proctitis: a subgroup analysis of the phase 3 ELEVATE UC 52 and ELEVATE UC 12 trials","volume":"17","author":"Peyrin-Biroulet","year":"2023","journal-title":"J\u00a0Crohns Colitis"},{"key":"10.1016\/j.cgh.2024.06.036_bib56","series-title":"Crohn's Disease: Developing Drugs for Treatment Guidance Document","year":"2022"},{"key":"10.1016\/j.cgh.2024.06.036_bib57","series-title":"Ulcerative Colitis: Developing Drugs for Treatment (Guidance Document)","year":"2022"},{"key":"10.1016\/j.cgh.2024.06.036_bib58","doi-asserted-by":"crossref","first-page":"i381","DOI":"10.1093\/ecco-jcc\/jjab232.507","article-title":"P380 Early improvement of endoscopic outcomes with risankizumab is associated with reduced hospitalisation and surgery rates in patients with Crohn\u2019s disease","volume":"16","author":"Feagan","year":"2022","journal-title":"J\u00a0Crohns Colitis"},{"key":"10.1016\/j.cgh.2024.06.036_bib59","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1053\/j.gastro.2020.03.039","article-title":"Deep remission at 1 year prevents progression of early Crohn's disease","volume":"159","author":"Ungaro","year":"2020","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2024.06.036_bib60","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1053\/j.gastro.2022.06.068","article-title":"CORE-IBD: a multidisciplinary international consensus initiative to develop a core outcome set for randomized controlled trials in inflammatory bowel disease","volume":"163","author":"Ma","year":"2022","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2024.06.036_bib61","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/S2468-1253(21)00474-X","article-title":"Treat to target versus standard of care for patients with Crohn's disease treated with ustekinumab (STARDUST): an open-label, multicentre, randomised phase 3b trial","volume":"7","author":"Danese","year":"2022","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2024.06.036_bib62","doi-asserted-by":"crossref","first-page":"2291","DOI":"10.1053\/j.gastro.2021.02.035","article-title":"An International consensus to standardize integration of histopathology in ulcerative colitis clinical trials","volume":"160","author":"Ma","year":"2021","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2024.06.036_bib63","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1053\/j.gastro.2022.10.014","article-title":"Intestinal barrier healing is superior to endoscopic and histologic remission for predicting major adverse outcomes in inflammatory bowel disease: the Prospective ERIca trial","volume":"164","author":"Rath","year":"2023","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2024.06.036_bib64","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1111\/apt.13408","article-title":"Development of interim patient-reported outcome measures for the assessment of ulcerative colitis disease activity in clinical trials","volume":"42","author":"Jairath","year":"2015","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.cgh.2024.06.036_bib65","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1111\/apt.13001","article-title":"A\u00a0retrospective analysis: the development of patient reported outcome measures for the assessment of Crohn's disease activity","volume":"41","author":"Khanna","year":"2015","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.cgh.2024.06.036_bib66","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1111\/apt.15726","article-title":"Development of the symptoms and impacts questionnaire for Crohn's disease and ulcerative colitis","volume":"51","author":"Dulai","year":"2020","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.cgh.2024.06.036_bib67","doi-asserted-by":"crossref","first-page":"2200","DOI":"10.1016\/S0140-6736(22)00688-2","article-title":"Ustekinumab versus adalimumab for induction and maintenance therapy in biologic-naive patients with moderately to severely active Crohn's disease: a multicentre, randomised, double-blind, parallel-group, phase 3b trial","volume":"399","author":"Sands","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.cgh.2024.06.036_bib68","article-title":"risankizumab versus ustekinumab for patients with moderate to severe Crohn's disease: results from the phase 3B SEQUENCE study","author":"Peyrin-Biroulet","year":"2023","journal-title":"UEG Week"},{"key":"10.1016\/j.cgh.2024.06.036_bib69","doi-asserted-by":"crossref","first-page":"i62","DOI":"10.1093\/ecco-jcc\/jjad212.0035","article-title":"OP35 efficacy of mirikizumab in comparison to ustekinumab in patients with moderate to severe Crohn\u2019s disease: results from the phase 3 VIVID 1 study","volume":"18","author":"Jairath","year":"2024","journal-title":"J\u00a0Crohns Colitis"},{"key":"10.1016\/j.cgh.2024.06.036_bib70","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.1016\/S0140-6736(15)00068-9","article-title":"Early combined immunosuppression for the management of Crohn's disease (REACT): a cluster randomised controlled trial","volume":"386","author":"Khanna","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.cgh.2024.06.036_bib71","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1002\/ueg2.12293","volume":"10","year":"2022","journal-title":"United European Gastroenterol J"},{"key":"10.1016\/j.cgh.2024.06.036_bib72","doi-asserted-by":"crossref","first-page":"2779","DOI":"10.1016\/S0140-6736(17)32641-7","article-title":"Effect of tight control management on Crohn's disease (CALM): a multicentre, randomised, controlled phase 3 trial","volume":"390","author":"Colombel","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.cgh.2024.06.036_bib73","doi-asserted-by":"crossref","first-page":"i92","DOI":"10.1093\/ecco-jcc\/jjad212.0051","article-title":"DOP11 Disease clearance after 16 weeks of treatment with vedolizumab in patients with moderate to severe ulcerative colitis: an interim analysis from the VERDICT trial","volume":"18","author":"Jairath","year":"2024","journal-title":"J\u00a0Crohns Colitis"},{"key":"10.1016\/j.cgh.2024.06.036_bib74","doi-asserted-by":"crossref","DOI":"10.1093\/ecco-jcc\/jjae026","article-title":"Pragmatic trial design to compare real-world effectiveness of different treatments for inflammatory bowel diseases: the PRACTICE-IBD European consensus","author":"Fantini","year":"2024","journal-title":"J\u00a0Crohns Colitis"},{"key":"10.1016\/j.cgh.2024.06.036_bib75","doi-asserted-by":"crossref","first-page":"i56","DOI":"10.1093\/ecco-jcc\/jjac190.0040","article-title":"OP40 PRA023 demonstrated efficacy and favorable safety as induction therapy for moderately to severely active UC: phase 2 ARTEMIS-UC study results","volume":"17","author":"Sands","year":"2023","journal-title":"J\u00a0Crohns Colitis"},{"key":"10.1016\/j.cgh.2024.06.036_bib76","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/S2468-1253(24)00034-7","article-title":"A\u00a0biomarker-stratified comparison of top-down versus accelerated step-up treatment strategies for patients with newly diagnosed Crohn's disease (PROFILE): a multicentre, open-label randomised controlled trial","volume":"9","author":"Noor","year":"2024","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2024.06.036_bib77","first-page":"251","article-title":"Advanced combination treatment with biologic agents and novel small molecule drugs for inflammatory bowel disease","volume":"19","author":"Solitano","year":"2023","journal-title":"Gastroenterol Hepatol (N Y)"},{"key":"10.1016\/j.cgh.2024.06.036_bib78","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/S2468-1253(22)00427-7","article-title":"Guselkumab plus golimumab combination therapy versus guselkumab or golimumab monotherapy in patients with ulcerative colitis (VEGA): a randomised, double-blind, controlled, phase 2, proof-of-concept trial","volume":"8","author":"Feagan","year":"2023","journal-title":"Lancet Gastroenterol Hepatol"}],"updated-by":[{"DOI":"10.1016\/j.cgh.2025.01.002","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000}}],"container-title":["Clinical Gastroenterology and Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1542356524006359?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1542356524006359?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,11]],"date-time":"2025-02-11T20:23:11Z","timestamp":1739305391000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1542356524006359"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2]]},"references-count":78,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,2]]}},"alternative-id":["S1542356524006359"],"URL":"https:\/\/doi.org\/10.1016\/j.cgh.2024.06.036","relation":{},"ISSN":["1542-3565"],"issn-type":[{"value":"1542-3565","type":"print"}],"subject":[],"published":{"date-parts":[[2025,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The Future of Clinical Trials in Inflammatory Bowel Disease","name":"articletitle","label":"Article Title"},{"value":"Clinical Gastroenterology and Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cgh.2024.06.036","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Inc. on behalf of the AGA Institute.","name":"copyright","label":"Copyright"}]}}